

eCommons@AKU

Department of Medicine

Department of Medicine

July 2013

Wilson's disease: experience at a tertiary care hospital.

Om Parkash *Agha Khan University,* om.parkash@aku.edu

Adil Ayub Aga Khan University

Wasim Jafri *Aga Khan University,* wasim.jafri@aku.edu

Syed H Shah Agha Khan University, hasnain.alishah@aku.edu

Saeed Hamid Aga Khan University, saeed.hamid@aku.edu

Follow this and additional works at: http://ecommons.aku.edu/pakistan_fhs_mc_med_med Part of the <u>Gastroenterology Commons</u>

Recommended Citation

Parkash, O., Ayub, A., Jafri, W., Shah, S., Hamid, S. (2013). Wilson's disease: experience at a tertiary care hospital.. *JCPSP: Journal of the College of Physicians and Surgeons--Pakistan*, 23(7), 525-526. **Available at:** http://ecommons.aku.edu/pakistan_fhs_mc_med_med/208

Wilson's Disease: Experience at a Tertiary Care Hospital

Om Parkash¹, Adil Ayub², Wasim Jafri¹, Syed Hasnain Alishah¹ and Saeed Hamid¹

ABSTRACT

Wilson's disease (WD) is a rare autosomal recessive disorder of copper metabolism. Data regarding WD is not available from Pakistan. A cross-sectional study was conducted at The Aga Khan University Hospital, Karachi, and all patients admitted with primary and secondary diagnosis of Wilson's disease were added. A total of 47 patients were seen; 68% (n = 32) were male. The mean age was 26.6 ± 9.97 years. Most of the patients presented with hepatic, (n = 22, 46.8%), neurological, (n = 17, 36.2%) and psychiatric (n = 8, 17%) symptoms. Mean ceruloplasmin level was 0.17 ± 0.13 g/dl; it was < 0.25 g/dl in 39 (86.6%) patients. Serum copper (Cu) was reduced in 32 (68.1%) patients and 24-hr-urinary Cu was raised in 22 (47.6%) patients. Slit lamp examination for Kayser-Fleischer (KF) rings was done on 15 (31.9%) patients and 9 (60%) of them had KF rings. Mean serum aspartate transaminase (AST) / alanine transaminases (ALT) ratio was 1.92 and median alkaline phosphatase / total bilirubin ratio was 79.30 (IQR 35.05; 166.50).

Key Words: Wilson's disease. Kayser-Fleischer (KF) ring. Serum copper.

Wilson's disease (WD) is a rare autosomal recessive disorder of copper metabolism, caused by decreased biliary copper excretion and deposition in liver, brain, kidneys and skeletal system. The patients present with a variety of clinical symptoms, the most common being liver disease, neurological and psychiatric disturbances.^{1,2} The diagnosis of WD is difficult because of lack of specific and sensitive tests for WD. Due to relative rarity of WD and lack of awareness among the physicians, this disease is not diagnosed early, at least in our country. Therefore, majority of patients present late with either decompensated liver disease or incapacitating neurologic disease.³ To the best of the authors' knowledge, there is very limited data and available literature on WD from Pakistan,⁴ so a crosssectional study was done at The Aga Khan University Hospital, Karachi. After data collection and analysis, a comparison with studies from India, Japan and Europe was made.5-7

A total of 47 patients were seen from 1985 to 2011, and 32 (68.1%) among them were male. The mean age of the patients was 26.6 ± 9.97 years. The most common presentation in this group of patients was hepatic, (n = 22, 46.8%), followed by neurological, (n = 17, 36.2%) and psychiatric (n = 8, 17%) patients. The patients with psychiatric symptoms had an earlier onset of disease at the mean age of 18.8 ± 3.3 years.

The clinical diagnosis of WD was confirmed with ceruloplasmin level, 24-hour-urinary copper and serum copper level (Table I). The two ratios (SGOT/SGPT,

Department of Medicine¹ / Medical Student², The Aga Khan University, Karachi.

Correspondence: Dr. Om Parkash, A-12, Pak Tameer Plaza, Gulshan-e-Iqbal, Block 14, Karachi. E-mail: om.parkash@aku.edu

Received: May 14, 2012; Accepted: March 19, 2013.

Table I: Diagnostic investigations for WD.	
¹ Ceruloplasmin levels (g/dl)	0.17 ± 0.13
² 24-hr urinary copper secretion* (ug/day)	155 (IQR 44.26; 407.75)
³ Serum copper (ug/dl)*	55.60 (IQR 34.42; 73.75)
AST/ALT ratio	1.92 ± 1.36
Alkaline phosphatase/ total bilirubin ratio*	79.30 (IQR 35.05; 166.50)
* Madian with interguartile ranges (IOP) has been reported	d for those veriables

1. normal values > 0.25g/dl, 2. normal values (70-160µg/dl) 3. Normal values 70-160µg/dl

Alk.P/T.Bil) which had been recently reported in a study in acute liver failure patients were also calculated. The mean value for AST/ALT ratio was 1.92 ± 1.36 and median value for Alk.P/T.Bil ratio was 79 (IQR 35.05; 166.50). MRI was done in 21 (84%) patients of neuropsychiatric group and 17 (81%) of these were found to have abnormal signaling within basal ganglia, consistent with WD.

The mean age at onset was slightly higher in this cohort as compared to other comparison studies. There was a higher burden of WD in male population, which is quite comparable with studies from India and Japan, but European study on the other hand had shown a higher female predominance (Table II). The most common mode of presentation in this cohort was hepatic, which is consistent with Japanese and European studies.^{5,7} Data from Indian study, however, has reported a high predominance of neuropsychiatric symptoms and a lower mean age-of-onset.⁶ This has also been observed in the present study that psychiatric mode of presentation was more common in younger age group with a mean age of presentation at 18.8 ± 3 years.

The diagnostic biochemical parameters in this study showed low ceruloplasmin levels in most of our patients. For those tested for 24-hr-urinary copper, less than half had raised levels. This is comparable with results from Japanese study, but on the contrary, studies from India and Europe had shown very high percentage of patients with raised 24-hr-urinary Cu levels. Similar trends were

	Pakistan	India (6)	Japan (7)	European countries (5)	
Year	2011	2007	2010	2007	
Study period	1985-2011	1970-2000	1999-2007	2000-2005	
Place of study	Karachi, Pakistan	Bangalore, India	Nagoya and Kanazawa,	Heidelberg, Germany	
			Central Japan		
Number of cases	47	282	30	163	
Male: Female	32:15	196:86	20:10	65:98	
Prevalence of males	68%	69%	66.6%	39.8%	
Mean age at onset (years)	26.6 (mean age at presentation)	15.9	17.5	17.4	
Symptoms					
Hepatic	22 (46.8%)	42 (14.9%)	22 (73.3%)	96 (58.9%)	
Neurological	17 (36.2%)	195 (69.2%)	5 (16.7%)	55 (33.7%)	
Psychiatric	8 (17%)	7 (2.48%)			
Other (i-e musculoskeletal, hemolytic or mixed symptoms)		38 (13.55%)	3 (10%)	12 (7.4%)	
Diagnostic tests					
Ceruloplasmin levels	Reduced in 86.6%	Reduced in 88%	-	Reduced in 88.2%	
Serum copper	Reduced in 68.1%				
Hepatic copper output				High in 92.7%	
24-hr urinary copper excretion	Raised in 47.6%	Raised in 96%	Raised in 36.4% with hepatic form and 40% with neurological form	Raised in 87.1%	
KF ring					
In hepatic form	Present in 28.6%	Present in 13.6%	Present in 41%	Present in 52.1%	
In neurological form	Present in 87.5%	Present in 100%	Present in 100%	Present in 85.5%	

Table II: Comparison of WD in Pakistan, India, Japan and European countries.

seen in ophthalmological examination with KF rings, which were present in almost all patients with neurological symptoms in all studies. However, the presence of KF rings in patients with predominantly hepatic symptoms varied in these studies.⁸

WD should be suspected in patients who have unexplained abnormal liver function tests and whose family history is positive for liver disease. Due to similar patterns of biochemical parameters in WD in all these different regions and due to high percentage of hepatic presentation in our country, a clinician should check for atleast three values in case of unexplained liver disease; namely (i) low ceruloplasminemia (ii) high 24-hr-urinary copper (iii) presence of KF rings on ophthalmic examination.

REFERENCES

- Roberts EA, Schilsky ML. A practice guideline on Wilson disease. *Hepatology* 2003; **37**:1475-92.
- 2. Stremmel W, Meyerrose KW, Niederau C, Hefter H, Kreuzpaintner

G, Strohmeyer G. Wilson disease: clinical presentation, treatment, and survival. *Ann Intern Med* 1991; **115**:720-6.

- Hancu A, Mihai MC, Axelerad AD. Wilson's disease: a challenging diagnosis. Clinical manifestations and diagnostic procedures in 12 patients. *Rev Med Chir Soc Med Nat Iasi* 2011; 115:58-63.
- Mansoor S, Naveed AK, Majeed A. Analysis of clinical and biochemical spectrum of Wilson disease patients. *Indian J Pathol Microbiol* 2012; 55:365-9.
- Merle U, Schaefer M, Ferenci P, Stremmel W. Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study. *Gut* 2007; 56:115-20.
- 6. Taly AB, Prashanth LK, Sinha S. Wilson's disease: an Indian perspective. *Neurol India* 2009; **57**:528-40.
- Tatsumi Y, Hattori A, Hayashi H, Ikoma J, Kaito M, Imoto M, et al. Current state of Wilson disease patients in central Japan. Intern Med 2010; 49:809-15. Epub 2010 Apr 30.
- Schrag A, Schott JM. Images in clinical medicine. Kayser-Fleischer rings in Wilson's disease. N Engl J Med 2012; 366:e18.

••••☆••••